

Publication

A novel pyrazolopyridine with in vivo activity in Plasmodium berghei- and Plasmodium falciparum-infected mouse models from structure-activity relationship studies around the core of recently identified antimalarial imidazopyridazines

JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)**ID** 3395654**Author(s)** Le Manach, Claire; Paquet, Tanya; Brunschwig, Christel; Njoroge, Mathew; Han, Ze; González Cabrera, Diego; Bashyam, Sridevi; Dhinakaran, Rajkumar; Taylor, Dale; Reader, Janette; Botha, Mariette; Churchyard, Alisje; Lauterbach, Sonja; Coetzer, Theresa L.; Birkholtz, Lyn-Marie; Meister, Stephan; Winzeler, Elizabeth A.; Waterson, David; Witty, Michael J.; Wittlin, Sergio; Jiménez-Díaz, María-Belén; Santos Martínez, María; Ferrer, Santiago; Angulo-Barturen, Iñigo; Street, Leslie J.; Chibale, Kelly**Author(s) at UniBasel** [Wittlin, Sergio](#) ;**Year** 2015**Title** A novel pyrazolopyridine with in vivo activity in Plasmodium berghei- and Plasmodium falciparum-infected mouse models from structure-activity relationship studies around the core of recently identified antimalarial imidazopyridazines**Journal** Journal of medicinal chemistry**Volume** 58**Number** 21**Pages / Article-Number** 8713-8722

Toward improving pharmacokinetics, in vivo efficacy, and selectivity over hERG, structure-activity relationship studies around the central core of antimalarial imidazopyridazines were conducted. This study led to the identification of potent pyrazolopyridines, which showed good in vivo efficacy and pharmacokinetics profiles. The lead compounds also proved to be very potent in the parasite liver and gametocyte stages, which makes them of high interest.

Publisher American Chemical Society**ISSN/ISBN** 0022-2623**edoc-URL** <http://edoc.unibas.ch/41499/>**Full Text on edoc** No;**Digital Object Identifier DOI** 10.1021/acs.jmedchem.5b01605**PubMed ID** <http://www.ncbi.nlm.nih.gov/pubmed/26502160>**ISI-Number** WOS:000364796100028**Document type (ISI)** Article